Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
Phase 3 N=21 Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=200 Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
Gestational Diabetes · Diagnoses Disease · Pregnancy in Diabetic
Primary: Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT) — 31; 13…
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=90 Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
Phase 4 N=156 Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
Bone Metabolism
Primary: Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA) — -0.69; -0.14 percent — p=0.170
N/A N=70 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Impaired Glucose Tolerance · Prediabetic State
Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943
N/A N=39 Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Prediabetic State
Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…
N/A N=21 Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
Obesity · Impaired Glucose Tolerance · Type 2 Diabetes Mellitus
Primary: Mean Percent Change From Baseline in Whole-body Insulin Sensitivity — 87.4; 63.1 percentage of change from baseline
N/A N=55 Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Intermittent Fasting · Metabolic Dysfunction-Associated Fatty Liver Disease
Primary: Transient Elastography-Controlled Attenuation Parameter — 319.5; 343.5; 291.5; 285.0 db/m
Phase 3 N=602 Actos Now for Prevention of Diabetes (ACT NOW)
Impaired Glucose Tolerance · Type 2 Diabetes
Primary: Prevention of Type 2 Diabetes — 16.1; 5.0 percentage of participants
Phase 4 N=24 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
N/A N=12 The Fasting II Study
Diabetes · Metabolic Diseases
Primary: Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week. — 104.7; 104.5 mg/dL
Phase 3 N=302 Enhancing Fitness in Older Pre-diabetic Veterans
Impaired Glucose Tolerance · Obesity · Diabetes
Primary: Fasting Insulin — 10.26; 10.39 uIU/ml
Phase 2 N=57 Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
N/A N=60 The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy
Excessive Diet Restriction
Primary: Insulin Sensitivity (HOMA-IR) — 0.05; 0.06 no unit
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005
N/A N=28 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Phase 2 N=91 A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790
Phase 1 N=27 A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
The Methodology Assessment of Glucose Dependent Insulin Secretion
Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001
N/A N=96 The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
Impaired Fasting Glucose
Primary: Cmax for Glucose in IFG Status Participants — 42.76; 47.40 mg/dL — p=0.0487
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
Phase 2 N=51 Peanuts and Glycemic Control
Type2 Diabetes · Cardiovascular Diseases
Primary: Fasting Plasma Glucose — -0.9; -0.4 mg/dL
Phase 2 N=6 Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
Type 1 Diabetes
Primary: Effectiveness of Closed Loop Diabetes Control — 136.9; 149.5 mg/dl
Phase 4 N=59 Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program
Type 2 Diabetes
Primary: Incidence of Type 2 Diabetes Mellitus — 1; 1 participants